There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Urogen Pharma (URGN – Research Report) and Ligand Pharma (LGND – Research Report) with bullish sentiments.
Stay Ahead of the Market:
Urogen Pharma (URGN)
Guggenheim analyst Kelsey Goodwin reiterated a Buy rating on Urogen Pharma today and set a price target of $40.00. The company’s shares closed last Wednesday at $10.39, close to its 52-week low of $9.03.
According to TipRanks.com, Goodwin is a 1-star analyst with an average return of -5.1% and a 26.7% success rate. Goodwin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Century Therapeutics, and Genelux Corp.
Currently, the analyst consensus on Urogen Pharma is a Strong Buy with an average price target of $33.71, implying a 213.9% upside from current levels. In a report released yesterday, Scotiabank also initiated coverage with a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
Ligand Pharma (LGND)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Ligand Pharma today. The company’s shares closed last Wednesday at $104.62.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of -7.2% and a 38.4% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Clover Health Investments, and InfuSystem Holdings, Inc.
Currently, the analyst consensus on Ligand Pharma is a Strong Buy with an average price target of $148.67, a 39.5% upside from current levels. In a report issued on April 10, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $143.00 price target.
Read More on URGN: